We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

219 hedge funds and large institutions have $9.31B invested in Ascendis Pharma A/S in 2024 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 79 increasing their positions, 69 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 25

14% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 69

13% more capital invested

Capital invested by funds: $8.28B → $9.31B (+$1.04B)

8% more funds holding

Funds holding: 203 → 219 (+16)

0% more funds holding in top 10

Funds holding in top 10: 17 → 17 (0)

1.23% less ownership

Funds ownership: 105.16% → 103.93% (-1.2%)

33% less call options, than puts

Call options by funds: $39.3M | Put options by funds: $58.8M

Holders
219
Holders Change
+16
Holders Change %
+7.88%
% of All Funds
3.14%
Holding in Top 10
17
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.24%
New
42
Increased
79
Reduced
69
Closed
25
Calls
$39.3M
Puts
$58.8M
Net Calls
-$19.5M
Net Calls Change
+$3.34M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$234M
2
ACA
Avoro Capital Advisors
New York
+$107M
3
CCM
Camber Capital Management
Massachusetts
+$94.5M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$66.9M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$45.5M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$182M
2
SI
Sofinnova Investments
California
-$100M
3
PBA
Paradigm Biocapital Advisors
New York
-$90.6M
4
Franklin Resources
Franklin Resources
California
-$84.4M
5
VPC
Vestal Point Capital
New York
-$67.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$67.9M -$2.73M -20,213 -4%
Voloridge Investment Management
27
Voloridge Investment Management
Florida
$59.3M +$6.86M +50,795 +15%
SL
28
Siren LLC
Connecticut
$51.9M +$47M +347,921 New
American Century Companies
29
American Century Companies
Missouri
$51.8M +$5.51M +40,772 +13%
RSCM
30
Rock Springs Capital Management
Maryland
$48.5M +$4.73M +35,000 +12%
Morgan Stanley
31
Morgan Stanley
New York
$46.7M +$19.7M +145,519 +87%
CS
32
Candriam SCA
Luxembourg
$42.2M +$11.7M +86,984 +45%
SEI Investments
33
SEI Investments
Pennsylvania
$40.9M +$1.24M +9,176 +3%
DFO
34
Duquesne Family Office
New York
$39.6M +$35.8M +265,040 New
AIP
35
ARS Investment Partners
New York
$39.3M +$1.35M +9,972 +4%
FAM
36
Fred Alger Management
New York
$38.6M -$6.6M -48,863 -16%
VPC
37
Vestal Point Capital
New York
$37.3M -$67.5M -500,000 -67%
TD Asset Management
38
TD Asset Management
Ontario, Canada
$36.6M +$20.7M +153,178 +153%
BNP Paribas Asset Management
39
BNP Paribas Asset Management
France
$36.4M +$10.9M +80,746 +50%
WP
40
Woodline Partners
California
$35.1M +$4.9M +36,252 +18%
SSA
41
Schonfeld Strategic Advisors
New York
$34.1M +$17.6M +130,384 +133%
PCH
42
Polar Capital Holdings
United Kingdom
$33.6M +$30.4M +225,000 New
Marshall Wace
43
Marshall Wace
United Kingdom
$33M +$25.8M +190,786 +630%
QGA
44
Q Global Advisors
Texas
$32.8M – – –
SVCM
45
Saturn V Capital Management
Texas
$29.9M +$11.8M +87,061 +77%
FC
46
Finepoint Capital
Massachusetts
$28.4M +$108K +800 +0.4%
Loomis, Sayles & Company
47
Loomis, Sayles & Company
Massachusetts
$27.6M +$8.51M +63,029 +52%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$26.8M -$2.71M -20,083 -10%
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$26.7M +$6.84M +50,631 +40%
Allspring Global Investments
50
Allspring Global Investments
North Carolina
$24.1M -$2.41M -17,842 -10%
1
2
3 4 5

ASND Hedge Fund Activity: Q3 2024 in Review

219 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2024, worth a combined $9.31B — up 13% from $8.28B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new ASND positions and 25 closed out — a net gain of 17 holders — while 79 added to existing stakes and 69 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $234M. The largest seller was Wellington Management Group, cutting an estimated $182M.

  • 219 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2024, up from 203 in Q2 2024.
  • Funds reported $9.31B of Ascendis Pharma A/S stock for Q3 2024, up 13% quarter-over-quarter.
  • 42 funds opened new Ascendis Pharma A/S positions in Q3 2024 and 25 closed out, a net change of +17 holders.
  • The largest Ascendis Pharma A/S buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $234M added.
  • The largest Ascendis Pharma A/S seller in Q3 2024 was Wellington Management Group, an estimated $182M sold.

Based on aggregated 13F filings for Q3 2024.